Global Health Ltd
Healthcare | Mid Cap
Global Health Ltd. demonstrates exceptional financial health, characterized by outstanding profitability, rapid growth, and a very strong, low-debt financial structure. The company consistently turns a significant portion of its revenue into profit and is expanding its sales, earnings, and asset base at an impressive rate. Its ability to manage long-term financial obligations is excellent, as it relies more on its own funds than on borrowing, which significantly reduces financial risk. The company is also very effective in managing its day-to-day operations, such as selling medical supplies quickly and collecting payments from customers promptly. A key area of note is its use of large-scale assets, like buildings and equipment, which currently generate lower revenue in proportion to their value. The company retains all its earnings to fuel its high growth, hence it does not pay dividends to shareholders.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio10.00
- Financial Ratio6.20
- Profitability Ratio10.00
- Efficiency Ratio7.33
- Coverage Ratio6.80
- Solvency Ratio10.00
- Liquidity Ratio8.30
- Peer Assessment
- Management AssessmentStrong
- Risk AssessmentStrong
- 1 HourNeutral
- 2 HoursBullish
- 4 HoursBullish
- 1 DayBullish
- 1 WeekBullish
- 1 MonthBullish
Global Health Ltd. demonstrates exceptional financial health, characterized by outstanding profitability, rapid growth, and a very strong, low-debt financial structure. The company consistently turns a significant portion of its revenue into profit and is expanding its sales, earnings, and asset base at an impressive rate. Its ability to manage long-term financial obligations is excellent, as it relies more on its own funds than on borrowing, which significantly reduces financial risk. The company is also very effective in managing its day-to-day operations, such as selling medical supplies quickly and collecting payments from customers promptly. A key area of note is its use of large-scale assets, like buildings and equipment, which currently generate lower revenue in proportion to their value. The company retains all its earnings to fuel its high growth, hence it does not pay dividends to shareholders.
Overall Valuation Score
P/E RATIO (TTM)
77.27
Industry Median
36.13
Mid Cap Median
51.09
P/E RATIO
74.08
P/B RATIO
10.54
Industry Median
6.08
Mid Cap Median
8.72
P/S RATIO
477.32
Industry Median
5.75
Mid Cap Median
8.76
Others
PEG RATIO
1.06
EV/EBITDA RATIO
38.90
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company is experiencing a period of outstanding and robust growth across all key financial areas. It has demonstrated an exceptional ability to increase its revenues, profits, and overall asset base. This comprehensive growth trajectory, from top-line sales to bottom-line earnings per share, indicates strong market demand for its services and effective execution of its expansion strategy. This makes the company a high-growth entity, which is a major positive for its future prospects.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 49.76 | 25.06 | 20.85 | 12.73 | 19.45 |
| Operating Profit Growth Rate | 132.49 | 39.08 | 27 | 9.52 | 3.72 |
| Earnings Per Share (EPS) Growth | 33.39 | 56.9 | 46.46 | 0.62 | 15.51 |
| Asset Growth Rate | 16.78 | 30.23 | 4.47 | 11.36 | 23.9 |
| Net Income Growth Rate | 575.86 | 66.33 | 46.63 | 0.63 | 15.18 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial metrics show a solid performance with some specific characteristics. Earnings per share, both on an adjusted and cash basis, are growing well, which is positive for shareholder value. The company's intrinsic book value is also increasing robustly. However, the company is making significant capital expenditures to expand, which is scored as a negative in this model. Furthermore, it does not distribute any of its earnings as dividends, instead retaining them for business reinvestment, which is a key part of its growth strategy.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 7.69 | 12.07 | 17.67 | 19.19 | 20.48 |
| Cash Earnings Per Share (Cash EPS) | 12.78 | 17.63 | 24.11 | 25 | 28.78 |
| Book Value Per Share | 63.37 | 89.96 | 107.63 | 125.44 | 146.74 |
| Dividend Per Share (DPS) | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures (CapEx) | 273 | 235 | 278 | 514 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company demonstrates an outstanding level of profitability across all measures. It is highly effective at managing its costs, resulting in strong margins from its core operations. Furthermore, it generates excellent returns on the capital invested by both shareholders and lenders. This superior profitability is a core strength, indicating a highly efficient, well-managed business with a strong market position that allows it to convert revenue into substantial profit.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 15.14 | 17.97 | 19.42 | 18.74 | 15.78 |
| Return on Capital Employed (ROCE) | 15 | 17 | 20 | 20 | 17 |
| Return on Equity (ROE) | 12.13 | 13.42 | 16.45 | 14.2 | 13.98 |
| Return on Assets (ROA) | 14.56 | 15.55 | 18.9 | 18.59 | 15.56 |
| Operating Margin | 21.14 | 23.51 | 24.7 | 24 | 20.84 |
| Net Margin | 9.04 | 12.03 | 14.6 | 13.03 | 12.56 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's operational efficiency presents a mixed picture. It excels in managing its working capital, demonstrating a strong ability to sell its inventory quickly and collect payments from customers in a timely manner. These are significant strengths that support healthy cash flow. However, the company appears less effective in utilizing its large, long-term assets, such as property and equipment, to generate sales. This suggests that the revenue generated from its substantial capital investments is relatively low.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 1.22 | 1.32 | 1.46 | 1.47 | 1.16 |
| Inventory Turnover Ratio | 39.55 | 39.35 | 41.56 | 44.78 | 50.88 |
| Receivables Turnover Ratio | 13.8 | 14.49 | 16.01 | 14.56 | 12.55 |
| Days Sales in Inventory Ratio | 9.23 | 9.28 | 8.78 | 8.15 | 7.17 |
| Receivable Days | 26.45 | 25.19 | 22.8 | 25.07 | 29.08 |
| Capital Turnover Ratio | 0.82 | 0.79 | 0.92 | 0.91 | 0.87 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's ability to cover its financial obligations shows a split performance. On one hand, its capacity to cover interest payments on its debt is excellent, thanks to its low level of borrowing and strong earnings. This demonstrates very low risk related to its debt. On the other hand, the company does not pay dividends to its shareholders, which means it does not have to cover any dividend payments. This lack of dividend payment negatively impacts the score in this category, despite being a strategic choice to reinvest earnings.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 4.27 | 6.22 | 8.46 | 9.74 | 10.05 |
| Equity Dividend Coverage Ratio |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company's solvency is in an exceptionally strong position. It has a very low reliance on debt to finance its assets, indicating that most of its operations are funded by equity from its owners. This conservative financial structure significantly reduces the risk of financial distress, making it highly resilient to economic downturns or interest rate fluctuations. This reflects a very stable and secure long-term financial foundation, appealing to risk-averse stakeholders.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.39 | 0.3 | 0.19 | 0.16 | 0.22 |
| Debt to Equity Ratio | 0.64 | 0.43 | 0.23 | 0.19 | 0.28 |
| Equity Ratio | 0.61 | 0.7 | 0.81 | 0.84 | 0.78 |
| Debt To Asset Ratio | 0.33 | 0.25 | 0.16 | 0.14 | 0.19 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company shows a very strong ability to meet its short-term financial obligations. It holds a substantial amount of cash and other liquid assets, more than enough to cover its immediate debts, which indicates excellent financial stability. This robust position provides a significant cushion against unforeseen expenses. However, the cash generated directly from its core hospital and diagnostic services is less strong compared to the assets it holds on its books. This suggests a contrast between the balance sheet's strength and the cash flow from daily operations.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.89 | 2.64 | 2.34 | 2.36 | 2.42 |
| Quick Ratio | 1.79 | 2.55 | 2.24 | 2.27 | 2.32 |
| Cash Ratio | 1.04 | 1.96 | 1.66 | 1.55 | 1.38 |
| Operating Cash Flow Ratio | 0.63 | 0.99 | 0.86 | 0.86 | 0 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Dr Lal Pathlabs Ltd | 8.79 | 55.19 | Highly Overvalued | 782.00 | 30.32 | 510.00 |
| 2 | Global Health Ltd | 8.22 | 74.08 | Neutral | 919.00 | 18.46 | 554.00 |
| 3 | J B Chemicals & Pharmaceuticals Ltd | 8.14 | 49.75 | Highly Overvalued | 1107.00 | 41.98 | 709.00 |
| 4 | Gland Pharma Ltd | 7.91 | 35.32 | Overvalued | 1630.00 | 78.88 | 1027.00 |
| 5 | Ajanta Pharma Ltd | 7.72 | 36.37 | Neutral | 1395.00 | 75.78 | 1056.00 |
| 6 | Syngene International Ltd | 7.44 | 56.02 | Overvalued | 918.00 | 7.55 | 317.00 |
| 7 | Emcure Pharmaceuticals Ltd | 7.40 | 35.96 | Neutral | 1865.00 | 38.66 | 941.00 |
| 8 | Laurus Labs Ltd | 7.10 | 83.16 | Neutral | 1778.00 | 13.72 | 890.00 |
| 9 | Narayana Hrudayalaya Ltd | 6.82 | 47.41 | Neutral | 1611.00 | 24.62 | 806.00 |
| 10 | Ipca Laboratories Ltd | 6.33 | 34.32 | Neutral | 1979.00 | 44.64 | 1184.00 |
| 11 | Krishna Institute of Medical Sciences Ltd | 5.93 | 130.97 | Neutral | 802.00 | 6.52 | 242.00 |
| 12 | Piramal Pharma Ltd | 5.83 | -65.39 | Neutral | 922.00 | 5.27 | -326.00 |
| 13 | Wockhardt Ltd | 5.07 | 151.73 | Neutral | 652.00 | 19.51 | 199.00 |
Management effectiveness is rated as strong, evidenced by robust financial performance and prudent financial management. The company demonstrates excellent growth in sales and profits, coupled with consistently improving margins. Capital efficiency metrics such as ROCE show a strong upward trajectory. Financial health is outstanding, with a declining debt-to-equity ratio and a strong, improving interest coverage ratio. The company's ability to maintain a negative cash conversion cycle indicates superior working capital management. While the promoter holding is relatively low and no dividends are paid, the overall data points to a highly capable management team focused on growth and operational excellence, supported by increasing interest from foreign institutional investors.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Compounded Sales Growth (5Y) | 25% | very strong |
| Compounded Profit Growth (5Y) | 81% | outstanding | |
| ROCE % (TTM) | 19.25% | strong | |
| Debt to Equity Ratio | 0.28 | excellent | |
| Cash Conversion Cycle | -34 days | outstanding | |
| Interest Coverage Ratio | 9.63 | very strong | |
| CONS | Dividend Payout % | 0% | weak |
| Promoter Holding | 33.04% | weak |
Financial Performance & Growth
The company has demonstrated excellent financial performance, characterized by strong and consistent growth in both revenue and profitability. Compounded sales growth over 5 years stands at an impressive 25%, with annual sales growth also showing robust figures. Profit growth has been outstanding, with a 5-year compounded growth of 81%, driven by a significant turnaround from FY21. This performance is supported by steadily improving operating profit margins (OPM), which have expanded from 14% in FY21 to 25% in FY24, indicating enhanced operational efficiency. Net profit margins have followed a similar upward trend. The contribution of other income to pre-tax profit is minimal, confirming that earnings are primarily generated from core business operations.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Sales Growth (%) | -3.6% | 49.8% | 25.0% | 20.9% |
| Profit Growth (%) | -20.0% | 578.0% | 67.0% | 46.0% |
| OPM (%) | 14% | 21% | 24% | 25% |
Capital Efficiency & Returns
Management has shown excellent proficiency in capital allocation, leading to superior returns. The Return on Capital Employed (ROCE) has seen a remarkable improvement, rising from a low of 5% in FY21 to 20% in FY24. This trend highlights the productive use of capital in generating profits. Similarly, the Return on Equity (ROE) has been healthy, recorded at 15% in the last year. The company's working capital management is a standout strength, evidenced by a consistently negative Cash Conversion Cycle (CCC). A negative CCC, which stood at -34 days in the latest year, signifies that the company receives payment from customers before it has to pay its suppliers, a highly favorable and efficient operational state.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| ROCE (%) | 5% | 15% | 17% | 20% |
| ROE (%) | 6% | 12% | 13% | 15% |
| Cash Conversion Cycle (Days) | -62 | -24 | -52 | -34 |
Financial Health & Prudence
The company's financial health is robust, reflecting prudent management of its liabilities. Debt levels are well-controlled and on a downward trend, with the debt-to-equity ratio improving significantly from 0.69 in FY22 to a very healthy 0.28 in FY24. This deleveraging demonstrates a commitment to a strong balance sheet. The Interest Coverage Ratio has strengthened considerably, increasing from 5.32 in FY22 to 9.63 in FY24, indicating a very comfortable capacity to meet interest payments from operating profits. This reduces financial risk substantially. The company has a consistent 0% dividend payout, which means profits are reinvested into the business for growth rather than distributed to shareholders.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| Debt / Equity Ratio | 0.69 | 0.46 | 0.28 |
| Interest Coverage Ratio | 5.32 | 7.41 | 9.63 |
| Dividend Payout (%) | 0% | 0% | 0% |
Shareholding & Ownership Structure
The shareholding structure presents a mixed picture. A notable weakness is the promoter holding, which is stable but relatively low at 33.04%. This is counterbalanced by strong and growing institutional interest, which is a significant positive. Foreign Institutional Investors (FIIs) have steadily increased their stake from 9.89% in March 2023 to 12.10% in March 2024, signaling confidence in the company's prospects. While Domestic Institutional Investors (DIIs) saw a slight dip in their holdings over the same period, their overall stake remains substantial. The combined institutional holding reinforces investor confidence, though the low promoter stake keeps the overall rating for this category at 'Average'.
| Metric | Mar 2023 | Mar 2024 |
|---|---|---|
| Promoter Holding (%) | 33.08% | 33.04% |
| FII Holding (%) | 9.89% | 12.10% |
| DII Holding (%) | 12.34% | 10.25% |
The overall risk profile for Global Health Ltd. is assessed as low. The primary strength mitigating risk is the high quality of its earnings, as evidenced by cash flow from operations consistently exceeding net profits. This indicates that reported profits are strongly backed by actual cash generation. Furthermore, the company's financial risk is minimal and decreasing. Active debt reduction has led to a low debt-to-equity ratio, and the very strong interest coverage ratio provides a substantial cushion against a downturn in operating performance. The combination of high-quality earnings and a prudent financial structure points to a low-risk profile from an operational and financial standpoint.
Accounting Quality
The company exhibits strong signs of high accounting quality. A key indicator is the relationship between cash flow from operations (CFO) and net profit (NP). Over the past three fiscal years, CFO has consistently been greater than net profit, with the CFO/NP ratio standing at 1.59, 1.98, and 1.28 for FY22, FY23, and FY24, respectively. This demonstrates that the company's reported earnings are not just an accounting entry but are being converted into actual cash, which is a hallmark of high-quality, sustainable profits.
| Metric | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|
| Cash Flow from Ops (Cr) | 311 | 645 | 612 |
| Net Profit (Cr) | 196 | 326 | 478 |
| CFO / NP Ratio | 1.59 | 1.98 | 1.28 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 101265.30Bearish
- SMA 201262.14Bullish
- SMA 501245.31Bullish
- EMA 101264.82Bullish
- EMA 201260.78Bullish
- EMA 501249.47Bullish
- DEMA 101267.40Bearish
- DEMA 201269.32Bearish
- DEMA 501263.92Bullish
- TEMA 101265.67Bearish
- TEMA 201269.32Bearish
- TEMA 501269.65Bearish
- MACD6.04Bearish
- ADX19.58Weak Trend
- IndicatorValueSignal
- RSI54.52Neutral
- CCI37.97Neutral
- ROC 90.36Bullish
- ROC 141.68Bullish
- ROC 251.20Bullish
- Stoch K55.15Neutral
- Stoch D56.34Neutral
- IndicatorValueSignal
- BB Upper1277.77Neutral
- BB Middle1262.14Neutral
- BB Lower1246.52Neutral
- ATR11.28Low Volatility
- IndicatorValueSignal
- MFI56.95Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 101261.36Bullish
- SMA 201249.42Bullish
- SMA 501236.74Bullish
- EMA 101260.63Bullish
- EMA 201252.82Bullish
- EMA 501239.30Bullish
- DEMA 101268.39Bearish
- DEMA 201265.56Bearish
- DEMA 501255.47Bullish
- TEMA 101268.35Bearish
- TEMA 201269.50Bearish
- TEMA 501258.58Bullish
- MACD9.74Bullish
- ADX21.60Weak Trend
- IndicatorValueSignal
- RSI58.97Neutral
- CCI78.31Neutral
- ROC 90.72Bullish
- ROC 141.58Bullish
- ROC 252.63Bullish
- Stoch K68.89Neutral
- Stoch D72.24Neutral
- IndicatorValueSignal
- BB Upper1280.87Neutral
- BB Middle1249.42Neutral
- BB Lower1217.97Neutral
- ATR15.92Low Volatility
- IndicatorValueSignal
- MFI64.63Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 101248.52Bullish
- SMA 201237.51Bullish
- SMA 501229.51Bullish
- EMA 101251.92Bullish
- EMA 201241.78Bullish
- EMA 501221.30Bullish
- DEMA 101264.23Bullish
- DEMA 201256.20Bullish
- DEMA 501260.65Bullish
- TEMA 101267.93Bearish
- TEMA 201262.00Bullish
- TEMA 50N/AN/A
- MACD11.71Bullish
- ADX23.80Weak Trend
- IndicatorValueSignal
- RSI60.57Neutral
- CCI133.36Overbought
- ROC 92.77Bullish
- ROC 143.09Bullish
- ROC 254.51Bullish
- Stoch K73.08Neutral
- Stoch D71.26Neutral
- IndicatorValueSignal
- BB Upper1271.89Neutral
- BB Middle1237.51Neutral
- BB Lower1203.13Neutral
- ATR24.51Low Volatility
- IndicatorValueSignal
- MFI84.10Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 101235.08Bullish
- SMA 201225.23Bullish
- SMA 501176.67Bullish
- SMA 1001131.67Bullish
- SMA 2001200.65Bullish
- EMA 101236.17Bullish
- EMA 201224.39Bullish
- EMA 501188.38Bullish
- EMA 1001170.60Bullish
- EMA 2001178.35Bullish
- DEMA 101247.54Bullish
- DEMA 201248.51Bullish
- DEMA 501230.88Bullish
- DEMA 1001173.35Bullish
- DEMA 2001166.17Bullish
- TEMA 101251.29Bullish
- TEMA 201243.86Bullish
- TEMA 501264.04Bearish
- TEMA 1001207.48Bullish
- TEMA 2001139.59Bullish
- MACD17.35Bearish
- ADX28.44Strong Trend
- IndicatorValueSignal
- RSI60.72Neutral
- CCI144.15Overbought
- ROC 145.82Bullish
- ROC 255.20Bullish
- Stoch K82.04Overbought
- Stoch D76.78Neutral
- IndicatorValueSignal
- BB Upper1269.99Neutral
- BB Middle1225.24Neutral
- BB Lower1180.48Neutral
- ATR37.57High Volatility
- IndicatorValueSignal
- MFI78.50Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 201128.40Bullish
- SMA 501216.21Bullish
- EMA 201163.44Bullish
- EMA 501174.98Bullish
- DEMA 201168.15Bullish
- DEMA 501170.10Bullish
- TEMA 201204.14Bullish
- TEMA 501128.96Bullish
- MACD11.21Bullish
- ADX18.41Weak Trend
- IndicatorValueSignal
- RSI54.32Neutral
- CCI10.56Neutral
- ROC 1411.26Bullish
- ROC 255.60Bullish
- Stoch K82.41Overbought
- Stoch D82.71Overbought
- IndicatorValueSignal
- BB Upper1283.15Neutral
- BB Middle1128.40Neutral
- BB Lower973.65Neutral
- ATR77.96Low Volatility
- IndicatorValueSignal
- MFI69.86Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 61107.73Bullish
- SMA 121194.99Bearish
- SMA 241170.00Bullish
- EMA 61136.54Bullish
- EMA 121154.23Bullish
- EMA 241110.65Bullish
- DEMA 61116.02Bullish
- DEMA 121145.91Bullish
- DEMA 24N/AN/A
- TEMA 61122.94Bullish
- TEMA 121102.25Bullish
- TEMA 24N/AN/A
- MACDN/AN/A
- ADX22.32Weak Trend
- IndicatorValueSignal
- RSI60.31Neutral
- CCIN/AN/A
- ROC 25-17.73Bearish
- ROC 50N/AN/A
- Stoch KN/AN/A
- Stoch DN/AN/A
- IndicatorValueSignal
- BB Upper1374.26Neutral
- BB Middle1168.63Neutral
- BB Lower963.00Neutral
- ATR172.81Low Volatility
- IndicatorValueSignal
- MFI51.79Neutral